tranexamic acid has been researched along with Rupture, Spontaneous in 24 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Rupture, Spontaneous: Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 9.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 7.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
| "Seventy patients with subarachnoid haemorrhage due to ruptured intracranial aneurysms were managed by delayed intervention (third week) along with the prescription of antifibrinolytic drugs (tranexamic acid 6 g/daily)." | 5.06 | [Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy]. ( Chabannes, J; Chazal, J; Commun, C; Irthum, B; Janny, P, 1986) |
| "The outcome of treatment with an antifibrinolytic agent (tranexamic acid) for six weeks after rupture of an intracranial aneurysm was assessed in a randomised controlled trial." | 5.04 | Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? ( Maurice-Williams, RS, 1978) |
| "A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm." | 5.04 | Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. ( Chandra, B, 1978) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 3.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "Glanzmann's thrombasthenia (GT) is a very rare autosomal recessive genetic bleeding disorder." | 1.38 | Giant abdominopelvic haematoma arising from ovulation in a Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal tranexamic acid. ( Bektas, O; Boyraz, G; Buyukasik, Y; Selcuk Tuncer, Z; Selcuk, I, 2012) |
| "An aneurysm-induced hydrocephalus was observed in two series of patients who were treated antifibrinolytically in different ways: A = 3 g/day of AMCA + 3 - 400,000 KIU/day of aprotinins, B = 6 g/day of AMCA." | 1.27 | Hydrocephalus following aneurysmal SAH. ( Gagliardi, FM; Spallone, A, 1983) |
| " The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects." | 1.26 | The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. ( Schisano, G, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (79.17) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schlitter, MC | 1 |
| Rühl, H | 1 |
| Thiesler, T | 1 |
| Penner, AH | 1 |
| Berens, C | 1 |
| Wolf, D | 1 |
| Mayer, K | 1 |
| Simon, T | 1 |
| Bakker, IS | 1 |
| Penninga, L | 1 |
| Nellensteijn, DR | 1 |
| Boama, V | 1 |
| Haynes, S | 1 |
| Buyukasik, Y | 1 |
| Boyraz, G | 1 |
| Selcuk, I | 1 |
| Bektas, O | 1 |
| Selcuk Tuncer, Z | 1 |
| Aiba, T | 1 |
| Spallone, A | 2 |
| Gagliardi, FM | 1 |
| Neil-Dwyer, G | 1 |
| Sharr, MM | 1 |
| Yamaura, A | 1 |
| Nakamura, T | 1 |
| Makino, H | 1 |
| Hagihara, Y | 1 |
| Fodstad, H | 2 |
| Ramirez-Lassepas, M | 1 |
| Maurice-Williams, RS | 2 |
| Alvarez Garijo, JA | 1 |
| Vilches, JJ | 1 |
| Aznar, JA | 1 |
| Watanabe, H | 1 |
| Ito, M | 1 |
| Chigasaki, H | 1 |
| Ishii, S | 1 |
| Chandra, B | 1 |
| Liliequist, B | 1 |
| Schannong, M | 1 |
| Thulin, CA | 1 |
| Van Rossum, J | 1 |
| Wintzen, AR | 1 |
| Check, W | 1 |
| Schisano, G | 1 |
| Tamaki, N | 1 |
| Kusunoki, T | 1 |
| Oi, S | 1 |
| Taomoto, K | 1 |
| Matsumoto, S | 1 |
| Tsementzis, SA | 1 |
| Hitchcock, ER | 1 |
| Meyer, CH | 1 |
| Pastore, FS | 1 |
| Rizzo, A | 1 |
| Guidetti, B | 1 |
| Kassell, NF | 1 |
| Haley, EC | 1 |
| Torner, JC | 1 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Commun, C | 1 |
| Chabannes, J | 1 |
| Janny, P | 1 |
2 reviews available for tranexamic acid and Rupture, Spontaneous
| Article | Year |
|---|---|
[The timing of surgical treatment for ruptured intracranial aneurysms--from the viewpoint of intentionally delayed operation (author's transl)].
Topics: Cerebral Hemorrhage; Fibrinolysis; Hemostasis; Humans; Intracranial Aneurysm; Methods; Rupture, Spon | 1981 |
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.
Topics: Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Ruptu | 1981 |
7 trials available for tranexamic acid and Rupture, Spontaneous
| Article | Year |
|---|---|
Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Fibrin F | 1980 |
Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Ru | 1978 |
Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.
Topics: Adult; Aged; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind | 1978 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
Antifibrinolytic agents for ruptured intracranial aneurysms.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Method; Humans; Intracranial Ane | 1978 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
[Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial Ane | 1986 |
15 other studies available for tranexamic acid and Rupture, Spontaneous
| Article | Year |
|---|---|
Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma.
Topics: Blood Component Transfusion; Chest Pain; Combined Modality Therapy; Disseminated Intravascular Coagu | 2014 |
Haemorrhagic rupture of hepatic simple cysts.
Topics: Abdominal Pain; Anticoagulants; Antifibrinolytic Agents; Cysts; Erythrocyte Transfusion; Hemoperiton | 2015 |
Conservative management of a haemorrhagic adnexal cyst in a patient with Type 3 von Willebrand Disease.
Topics: Abdominal Pain; Adult; Antifibrinolytic Agents; Blood Component Transfusion; Coagulants; Factor VIII | 2011 |
Giant abdominopelvic haematoma arising from ovulation in a Glanzmann's thrombasthenia patient with platelet refractoriness: treatment with surgery and intra-abdominal tranexamic acid.
Topics: Adult; Corpus Luteum; Female; Hematoma; Humans; Ovarian Cysts; Ovulation; Rupture, Spontaneous; Thro | 2012 |
Hydrocephalus following aneurysmal SAH.
Topics: Apoproteins; Drug Therapy, Combination; Humans; Hydrocephalus; Intracranial Aneurysm; Intracranial P | 1983 |
Ruptured intracranial aneurysms.
Topics: Cerebrovascular Circulation; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Rupture, Sp | 1983 |
Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Blood Pressure; Cerebral Cortex; Cisterna Magna; Cyclohe | 1980 |
Ruptured intracranial aneurysms: has the incidence of early rebleeding been over-estimated?
Topics: Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Middle Aged; Recurr | 1982 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.
Topics: Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Intracranial Aneurysm; Rupture, Spontaneous; Suba | 1976 |
What about medical therapy alone?
Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneu | 1978 |
The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cyclohexanecarboxylic Acids; Humans; Int | 1978 |
[Clinical study on rebleeding of cerebral anuerysms--with special references to the warning signs of rebleeding and antifibrinolytic treatment during waiting time for surgery (author's transl)].
Topics: Adult; Age Factors; Aged; Blood Pressure; Female; Humans; Hypnotics and Sedatives; Intracranial Aneu | 1975 |
Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms.
Topics: Adult; Aprotinin; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1987 |
Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage.
Topics: 4-Aminobenzoic Acid; Aminocaproates; Antifibrinolytic Agents; Humans; Intracranial Aneurysm; para-Am | 1986 |